Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alimera Sciences Inc (NASDAQ:ALIM)

During the Trading Day
3.22 +0.08 / +2.55%
As of 1:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
3.22 0.00 / 0.00%
Volume: 581.00
Health Technology

Company Description

Alimera Sciences, Inc. operates a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Alimera Sciences was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.

Contact Information

Alimera Sciences, Inc.
6120 Windward Parkway
Alpharetta Georgia 30005
P:(678) 990-5740
Investor Relations:



Mutual fund holders8.62%
Individual stakeholders54.73%
Other institutional46.05%

Top Executives

Charles Daniel MyersPresident, Chief Executive Officer & Director
Richard S. EiswirthSecretary, Chief Operating & Financial Officer
Kenneth GreenChief Scientific Officer & Senior Vice President
Susan H. CaballaSenior VP-Regulatory & Technical Affairs
David R. HollandSenior Vice President-Sales & Marketing